Used as a potent and selective inhibitor of JAK1 (Janus Kinase 1), a key enzyme in cytokine signaling pathways involved in inflammation and immune responses. It is developed for the treatment of immune-mediated disorders, such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.

Due to its high selectivity for JAK1, it minimizes off-target effects compared to less specific JAK inhibitors, improving safety and efficacy profiles. It is currently under clinical investigation to confirm its effectiveness and optimal dosing for treatment.

Additionally, it shows potential for treating other conditions involving immune system overactivation and chronic inflammation, particularly in patients unresponsive to conventional therapies.